Introduction
============

Schistosomiasis is a chronic and debilitating disease which affects millions of people, particularly the rural poor in the developing world. Of some 600 million people at risk, an estimated 200 million are infected, more than half of which are symptomatic and at least 20 million exhibit severe disease manifestations ([@b66]). Schistosomes, the causative agents, are parasitic bloodflukes (Phylum: Platyhelminth; Class: Trematoda) with indirectly transmitted life-cycles involving obligatory alternation of generations between sexual reproduction in a mammalian host and asexual reproduction within a molluscan (freshwater snail) host ([Fig. 1](#fig01){ref-type="fig"}). The free-living molluscan intermediate host-infecting larval stages, miracidia, arise from eggs passed in faeces or urine of the mammalian definitive host which hatch in freshwater. Following asexual replication in the intermediate host, cercariae are released which are infective to the mammalian host, when the hosts come into contact with infected water. Cercariae actively invade skin, transform to schistosomula and then migrate through the blood vasculature to the final maturation site, the hepatic portal and mesenteric venous systems for *Schistosoma mansoni* (prevalent in sub-Saharan Africa and South America) and *Schistosoma japonicum* (prevalent in South-East Asia)*,* and the blood vessels of the urogenital system for *Schistosoma haematobium* (prevalent in sub-Saharan Africa)*.* Of the three main schistosome species of public health importance, infection with *S. japonicum* and *S. mansoni* is associated with chronic hepatic and intestinal fibrosis, whilst *S. haematobium* infections can lead to ureteric and bladder fibrosis, calcification of the urinary tract and bladder cancer due to the retention of schistosome eggs within tissues and inflammatory response to them ([@b116]).

![The schistosome life-cycle incorporating some of the potential effects of mass chemotherapy schistosomiasis control programmes on the different parasite life stages.](eva0001-0066-f1){#fig01}

Current schistosome control programmes
--------------------------------------

There is currently no effective vaccine against human schistosomiasis and interruption of the transmission cycle through mollusciciding, biological control of the intermediate snail hosts and health education have generally proved insufficient control methods on their own ([@b44]). In areas where schistosomiasis is highly endemic therefore, the present goal is to mitigate the burden of the disease by controlling morbidity ([@b44]). Chemotherapy with praziquantel (PZQ) is the mainstay for schistosomiasis morbidity control, and will remain the drug of choice for the foreseeable future; the 54th World Health Assembly recently set a target of treating at least 75% of school-age children in areas with high schistosomiasis burdens by 2010 ([@b24]). Linked to this objective, the Schistosomiasis Control Initiative (SCI), established in 2002 with funding from the Bill & Melinda Gates Foundation, has assisted six sub-Saharan African countries (Burkina Faso, Mali, Niger, Tanzania including Zanzibar, Uganda and Zambia) to develop and implement sustainable schistosomiasis morbidity control programmes. The strategy included the donation of PZQ for mass treatment for schistosomiasis and co-administering, where appropriate, albendazole for soil-transmitted helminthiasis (STH, caused by the nematodes *Ascaris*, *Trichuris* and hookworm), combined with the provision of health education. Over the 5 years of the SCI program to date, more than 43 million treatments have been delivered in the six countries. Furthermore, the most recent 1.5 million were treated within an integrated program covering an additional set of neglected tropical diseases (NTDs) which include lymphatic filariasis, onchocerciasis and the bacterial disease trachoma. In all countries the impact of annual treatments on the prevalence and intensity of schistosome and STH infection has been impressive ([@b70]; [@b131]). Likewise, a range of morbidity indicators, such as anaemia, liver, spleen and bladder pathologies, have all also been significantly reduced as a response to treatment ([@b68],[@b69], [@b70]; [@b126]).

The role of evolution in schistosomiasis control
------------------------------------------------

In both the design and evaluation of the success of such programmes it is very important to consider the parasites and hosts as active and dynamic forces subject to evolutionary pressures. Evolutionary theory must therefore play a role both in the monitoring and evaluation, and in predicting the longer-term impact, of these and future programmes. The recent shift towards mass antischistosome chemotherapy may be expected to lead to intensive and prolonged new selection pressures on the parasites in particular, leading to a range of genotypic and phenotypic changes over space and time. The history of the use of drugs to treat infection shows clearly that in the vast majority of cases, if the selective pressure exerted by the drug is sufficiently strong at the population level, resistant strains of the infectious agent evolve and prosper. The emergence of resistance is almost always (particularly where resistance is a recessive trait) sigmoid in form over time, where little evidence for resistance is observed for many years before exponential growth in frequency towards a plateau. The magnitude of the plateau depends on many factors including the intensity of selection and the relative fitness of wild type and resistant organisms. The time scale of emergence and gene frequency change depend on the intensity of the selective pressure and the generation time of the pathogen, being a few days for many viruses to many months to years for complex multi-cellular organisms such as helminths.

Previous studies have shown that, in the laboratory at least, a range of different specific selective pressures imposed on schistosomes can produce rapid changes in parasite infectivity, fecundity, virulence (here defined as harm to the host), drug resistance and population genetic structure within only a few generations ([@b40]; [@b30]; [@b31]; [@b118]; [@b119]; [@b123], [@b124], [@b125], [@b127]; [@b56], [@b57]). Such selection pressures may also be predicted to influence the dynamics of inter-specific parasite interactions such as those between different species of schistosomes and between schistosomes and other co-infecting parasites, some of which are also being targeted in these control programmes ([@b37]; [@b45]). Parasite evolution can be a key obstacle in the development of any effective disease control programmes. Whilst drug resistance is the most obvious example, the possibility that pathogen life history characteristics, in particular virulence, but also parasite infectivity, diversity, population subdivision and transmission strategies, could also evolve under field conditions is beginning to attract the attention of evolutionary biologists ([@b38]; [@b129]). Knowledge on how the phenotype and genotype of parasite populations may change in response to such selective pressures may therefore have important implications for the long-term success of control programmes.

Impact of mass chemotherapy on schistosome parasites
====================================================

Evolution of drug resistance
----------------------------

Anthelmintic resistance is defined as a heritable change in a population of worms that enables their survival after chemotherapeutic treatment regimes that have previously proved to be effective against the same species and stage(s) of infection. Resistance emerges and establishes as the selective advantage of the drug resistant phenotype exceeds that of the wild type at the population level, which includes within the host and within the host population. Both populations are of relevance as a strongly resistant phenotype will only prosper if it retains an ability to transmit between hosts. Suboptimal drug concentrations, to those defined as optimal in clinical trials, can pertain as a consequence of the pharmacokinetics and pharmacodynamics of the drug mediated by host genetic background, adherence to recommended drug regimens and other factors such immune-incompetence and nutritional state of the host. Natural selection is the driving force in all biological systems and with population level application of drug treatments the risk of parasites evolving various ways to combat the impact of the drug on survival and reproduction will always exist.

The reliance of human helminth control programmes on a small number of drugs and the limited investment in antiparasitic discovery by pharmaceutical companies makes the control of these diseases highly vulnerable to the emergence and spread of drug resistance ([@b44]). In parasites of veterinary importance, reports of resistance have been made in every livestock host and to every anthelmintic class. In some locations multi-drug resistance has spread to such an extent that it has jeopardized the small ruminant industry ([@b97]). The public health community must learn from current problems in the field of veterinary medicine and seek to protect the effectiveness of existing safe and efficacious human antihelminthic drugs (and the investment incurred to develop them), particularly as there are generally few or no alternatives to be expected in the near future. This may be particularly pertinent for antischistosome control, since there is currently only PZQ available ([@b44]). Furthermore, there is ample evidence of the ability of the schistosome parasites to evolve drug resistant mechanisms under field conditions, as has already become apparent in the case of oxamaniquine, which was in wide use prior to the development and use of PZQ ([@b64]; [@b23]; [@b40]; [@b41]; [@b12]).

Fortunately, to date, there is no evidence to suggest that schistosomes have already developed and/or established resistance to PZQ under field conditions, even within China despite its widespread use for over 20 years ([@b35]; [@b34]). However, clinical investigations carried out, primarily in Egypt and Senegal on *S. mansoni* ([@b62]; [@b61]), the occasional reports of individual failures of PZQ in treatment of travellers with schistosomiasis ([@b4]), and the results from a range of laboratory studies and successful artificial-selection of resistance lines, continue to raise concerns about the existence or development of potential PZQ resistance in the future ([@b35]). A further cause for potential concern is the fact that the mode of action of PZQ, and the mechanisms and/or genetics of resistance in laboratory strains, still remains to be elucidated. Recent work has, however, indicated an important role for voltage-gated calcium channels, in particular the variant β subunit ([@b59]) to PZQ sensitivity, although other laboratory studies ([@b114]) suggest that multiple mechanisms of resistance may be possible. This is an important consideration in predicting and monitoring the impact of mass control on the evolution of drug resistance, as such a phenotype could be predicted to emerge in different populations through varying mutations which may have different competitive advantages.

The likelihood and rate of drug resistance emerging is dependent on the underlying genetics of resistance, the frequency of resistance genes in the population, the generation time of the parasite and the strength of selection pressure imposed. One determinant of the strength of selection for drug resistance is the proportion of the population in *refugia* at the time of treatment. *Refugia* provide a pool of susceptible genes that can dilute the resistant genes in the population, and are now considered critical in the management of drug resistance in the small ruminant industry ([@b115]). For example, high levels of multi-drug resistance to albendazole, tetramisole and ivermectin were detected in the nematode parasites (predominantly *H*a*emonchus contortus* and *Trichostronglyus* spp.) of a goat flock in Eastern Ethiopia but not in a separately managed sheep flock in the same area, that had high levels of *refugia* due to communal grazing of the sheep with other animals (cattle, goats, camels and horses). Moreover it was demonstrated that drug resistance in the goat flock could be reversed by introducing communal grazing with the susceptible sheep population ([@b105]). For human mass chemotherapy treatment of schistosomes such *refugia* are naturally present, and could presumably, hypothetically at least, be used in a similar way if PZQ-resistance was to emerge in human populations. The sizes of *refugia* are unknown but are likely to be high under current treatment schedules. PZQ is short-acting and generally given only annually (in contrast to the, up to, bimonthly frequency commonly used in animal husbandry) and a significant proportion of parasites will be in untreated individuals \[such as adults or preschool children ([@b90])\], alternative reservoir host species (see below), the intermediate snail hosts or as free-living stages. Moreover, immature schistosomes are not susceptible to PZQ action ([@b54]), and thus may also act as *refugia.* Size of *refugia* might, however, be expected to differ between schistosome species since *S. japonicum,* for example, is thought to have multiple domestic and wildlife reservoir hosts, in contrast to, for example, *S. haematobium*, which is essentially a human parasite. Such high levels of *refugia* for schistosomes suggests that the likelihood of drug resistance and rate of spread will be low, contrasting markedly with for example the filarial nematodes, *Onchocerca volvolus* (the causative agent of river blindness) and *Wuchereria bancrofti* and *Brugia malayi* (causative agents of lymphatic filariasis), where there is some concern of reduced efficacy of Ivermectin (IVM) in humans in some areas ([@b92]). These parasites are thought to have low levels of *refugia* as they have no free-living stages or reservoir hosts in their life-cycle, and only a small proportion of the population at any one time being present in their insect vector.

Another critical component of the strength of selection for the development of drug resistance will be the fitness of drug resistant individuals compared to susceptible individuals in the absence of drug pressure. Studies in Egypt have shown no increase of drug failure despite 10 years of therapeutic pressure in villages where there had previously been treatment failures due to the presence of worms with decreased sensitivity to PZQ ([@b62]; [@b14]). One possible explanation as to why and how these resistant worms have not become a more significant portion of the schistosome population is an inherent 'cost of resistance', whereby resistant genotypes are less fit than their susceptible counterparts in the absence of drug pressure, thereby limiting their establishment and spread. In all other pathogens that have been studied intensively under drug pressure, reduced fitness of the resistant strains in the absence of drug pressure has been recorded in the early stages of the emergence of resistance. Subsequently, however, especially in bacteria, compensatory mutations or genetic changes occur to increase the fitness of the resistant variants relative to wildtype ([@b73]; [@b91]). Drug resistant parasites may incur costs such as a lower reproduction rate, especially in the schistosome system where parasites may be required to co-adapt successfully to both their intermediate and definitive hosts. Indeed, resistant strains have been shown in the laboratory to exhibit reduced cercarial output and/or increased virulence to their intermediate host compared to susceptible strains, with some reverting to susceptibility with repeated lifecycle passage under no treatment ([@b71]). Mathematical models of selection and evolution have recently been applied to the issue of the development of anthelmintic resistance. Such models have identified, for instance, those parameters which will be most important in determining the impact of mass chemotherapy, and therefore those which should be most closely monitored when evaluating this impact. The change in frequency of resistant strains has been predicted to depend on the interplay between their relative fitness, the degree of selection pressure exerted by the drug treatments and even the life-cycle stages on which density dependence operates within the host-parasite system to regulate parasite abundance ([@b43]; [@b22]). One such model has predicted that if parasite reproduction and virulence are linked to resistance, then drug treatment may lead to the establishment of multiple parasite strains with many different levels of resistance, though resistance levels are expected to remain relatively low when resistance has a cost to the parasites ([@b43]). Other models have however suggested that, even with inherent costs of resistance, higher chemotherapeutic treatment rates, as are now being dispensed within sub-Saharan Africa, might allow both parasites with lower drug resistance to successfully invade and co-existence between susceptible and resistant parasite strains ([@b130]). The study of models that meld population genetics and transmission dynamics is in its infancy. Much biological complexity is poorly understood (such as whether the prime resistance gene will be dominant or recessive) and as such the predictive capability of these models is limited at present. To improve their predictive power, more needs to be understood about the mechanisms of resistance and relative fitness properties throughout the complex life cycles of schistosomes. Our current ignorance therefore demands that careful monitoring for the potential evolution of such resistance is part of all mass chemotherapy based control programmes.

Our ability to detect the emergence of anthelmintic resistance and to monitor its spread has indeed been declared as a priority ([@b97]). Monitoring should include *in vitro* and *in vivo* drug efficacy assays, pharmacokinetic analyses and ideally the monitoring of molecular markers associated with resistance to PZQ ([@b107]). A variety of *in vitro* and *in vivo* assays are available, although whether they are always good indicators of the susceptibility-resistance status of parasites has been questioned ([@b107]). An alternative promising method of investigating the possibility of drug resistance in helminth infections of humans is based on the notion that if rare resistance-conferring alleles were already present in untreated parasite populations, their frequency would increase with chemotherapeutic selection pressure. To test this notion it is necessary to: (i) identify polymorphic genes that are undergoing treatment-induced selection; (ii) demonstrate that the favoured alleles may confer a fitness advantage to the parasites carrying them in the presence of the drug; and (iii) link observed (normal and suboptimal) patterns in response to treatment with parasite phenotype and genotype before and after repeated treatment. As drug resistance is a genetic trait, molecular (DNA) markers perhaps hold the greatest promise for identifying the development of drug resistance to anthelminthics, and hence enable further monitoring and subsequent management of any spread of such resistance. The early stages of an effect of treatment would be manifested as a change in frequency and/or diversity of alleles linked to resistance. For example, one recent study reported changes in gene diversity, heterozygosity and in the number of markers not in Hardy--Weinberg equilibrium in 28 genetic markers spanning the P-gylcoprotein locus -- which is thought to be linked to ivermectin (IVM) sensitivity -- of four *O. volvulus* populations from the Volta Region of Ghana. The authors thereby concluded that the use of IVM for onchocerciasis control has imposed strong selection on *O. volvulus* populations ([@b7]). This conclusion should not surprise us -- it is to be expected in all mass treatment programmes for all pathogens. However, for many systems, such as schistosomes and PZQ, molecular markers linked to potential resistance genes are currently not available. An international consortium has recently been formed to develop anthelmintic resistance single nucleotide polymorphism (SNP) markers for detecting anthelmintic resistance ([@b97]). Such markers would ideally be mechanistically associated with the drug resistance phenotype (informative), but could simply be strongly associated without a mechanistic link (noninformative). Development of such markers will however be a lengthy progress, particularly given the lack of mechanistic knowledge concerning PZQ action or resistance. Furthermore the association study design used to identify informative SNPs requires the existence of two populations, one that exhibits a particular phenotype and one that does not, and hence makes such studies difficult in schistosome populations where drug resistance is not well characterized. This leaves noninformative markers as an option to detect the emergence of resistance, although the large amount of genetic diversity present in schistosome populations indicates that a very large number of noninformative SNPs would be necessary in order to find any significant associations with resistance phenotypes ([@b99]).

In the absence of such currently available molecular markers linked to resistance/susceptibility traits, population genetic studies with neutral markers such as microsatellites can provide valuable information about population genetic changes linked to the emergence of drug resistance. These include whether infections of previously treated people represent treatment failures (and therefore putatively 'resistant parasites') or new infections, enabling identification of sources of re-infection, as well as providing important understanding of how microevolutionary forces, such as migration, gene flow and genetic drift, might affect the evolution of drug resistance. Studying movement in parasites and hosts is important for understanding the evolution of drug resistance. For example, the widespread occurrence of drug-resistant *Plasmodium falciparum* was shown to result from the recent spread of a few selected alleles, rather than from the independent evolution of new resistance alleles in multiple locations ([@b87]; [@b100]). Indeed one recent study has reported that gene diversity in the P-glycoprotein locus in *O. volvolus* was reduced even in worms sampled from people in neighbouring untreated regions, and suggested that movements of IVM-treated worms by the fly vector could be responsible ([@b7]). Such investigations have recently begun in the schistosome system following the development of microsatellite markers for the three major species of human schistosomes: *S. mansoni* ([@b36]; [@b11]), *S. japonicum* ([@b103]) and *S. haematobium* ([@b53]). For example, in an initial study, adult worms from seven populations of *S. mansoni* from Kenya were examined using five microsatellite markers with a high level of genetic diversity detected suggesting that the strong genetic structure observed was a result of limited gene flow and large population sizes ([@b3]). An interesting hypothesis to emerge from this study was that limited gene flow between populations might hinder the development of drug resistance. Large scale population genetic studies as part of the monitoring and evaluation of mass human chemotherapy programmes should investigate a range of factors. These include the genetic diversity, presence and nature of population structure and gene flow in human helminth populations over space and time, estimates of effective population sizes from allele frequency data and any changes mediated by mass treatment, in order to determine the impact of treatment on the parasite population as a whole. A key problem militating against studies of schistosomes has, however, been that adult worms cannot be directly sampled from living hosts, because of their location deep within the blood vessels surrounding the intestine and bladder. Traditional indirect sampling involving passage through laboratory animals in order to obtain parasite material for analysis presents significant ethical and practical drawbacks, and may result in sampling biases such as bottlenecking processes and/or host-induced selection pressures. Recent new methodologies involving advances in room temperature DNA storage and mutliplexing are allowing direct genotyping of individual field collected larvae from infected people ([@b104]; [@b58]). These new methodologies, which have obvious ethical and biological advantages, represent an enormous reduction in the logistical effort required in assaying schistosome populations. For the first time there is now the opportunity to collect samples from a large number of infected human individuals at multiple locations.

Evolution of parasite life histories
------------------------------------

The evolution of drug resistance is only one dimension of potential parasite adaptation to human intervention through mass chemotherapy. Parasite life-history traits, including a parasite's survivorship and fecundity within a host, will evolve in response to selection and their evolution will be constrained by trade-offs between traits ([@b93]). Large scale use of chemotherapeutic agents against human helminth disease is likely to result in traits other than those associated with anthelminthic resistance being under potentially strong selection -- the ultimate prerequisite being heritable variation on which selection can act. It has been suggested, for example, that when anthelmintics reduce adult life expectancy, natural selection will favour parasites that mature earlier ([@b78]; [@b95]) allowing parasites to produce eggs before the host is given anthelminthics but which would result in worms which were smaller and less fecund. Conversely, [@b106] argued that parasitic nematodes with larvae in host tissues (poorly susceptible to treatments) and adults in the gastrointestinal tract (highly susceptible to treatment) should postpone maturity, become larger and more fecund. These hypotheses were investigated in *Teladorsagia cicumcinta* worms infecting sheep, where resistance to one group of antheminthics, the benzimidazoles, is controlled by a point mutation on the β-tubulin gene, allowing easy genotyping of worms into resistant or susceptible categories within individual isolates over a series of drug treatments ([@b72]). The authors reported that adult worms became larger when subjected to massive chemotherapy, in agreement with [@b106] hypothesis. Differences in schistosome susceptibility to PZQ has also been documented and one hypothesis has been a delayed maturation rate in Senegal ([@b42]) although it is not known if this could be due to previous PZQ exposure.

Another key component of parasite fitness which has attracted attention in theoretical studies is the evolution of parasite-induced harm to the host, or virulence ([@b19]). Virulence can in some circumstances represents a cost to parasites, through reducing the duration of infection and thus transmissibility, and is thus a key source of selection via its impact on reproductive success. The virulence of parasites is of importance in schistosomiasis control, as the aim of mass chemotherapy control programs is the reduction of parasite-induced host morbidity. Drug treatment with PZQ, in the absence of drug resistance, will directly reduce parasite infection intensity (i.e. the numbers of parasites present) but evolutionary changes in parasite virulence characteristics might affect, either positively or negatively, the impact of such effects on human morbidity.

A considerable body of theory has been developed to explain how nonzero levels of virulence can evolve and be maintained as a result of parasite adaptive evolution where, for example, increased virulence is concomitant with increased parasite reproduction despite a reduced duration of infection. Current theory predicts that though virulence is costly to the parasite, it may be maintained or promoted where the fitness costs of being virulent are offset by benefits such as increased transmission, dominance in intra-host competitive interactions, or the ability to withstand host defences ([@b75]; [@b47]). Such models most often assume that virulence is a direct side-effect of increased parasite reproduction, but that such increased reproduction also increases the probability of transmission to new hosts, or parasite competitive ability ([@b19]), resulting in a trade-off between traits and an 'optimum' virulence level that maximizes parasite fitness. This has led to ideas of virulence management ([@b33]) and specific predictions about, for instance, public health strategies which could prompt the evolution of benign parasites ([@b39]) or create the conditions which would favour more virulent pathogens ([@b51]). For example, Porco and colleagues extended the adaptive trade-off model to consider the effect of chemotherapeutic treatment on such trade-offs ([@b94]). They considered that treatment exerts selective pressure by reducing the duration of an infection, and hence opportunities for continued reproduction, thereby reducing the value of duration-increasing strategies to the pathogen and favouring pathogen strategies that maximize the rate of transmission. Thus when virulence is subject to such a trade-off, treatment can lead to an increase in optimal virulence. In other scenarios, however, such as if there is a trade-off between virulence and host activity levels, which may determine opportunities for contacts with other susceptible hosts, they concluded that treatment decreases the optimal virulence. Theoretical studies based on parasite adaptive evolution have also proposed multiple or mixed genotype infections as a further mechanism to promote the maintenance and evolution of virulence in parasite populations, as intra-host competition can favour high virulence parasite strains of lower potential fitness than less virulent strains wherever they have a local growth or transmission advantage ([@b6]; [@b76]). This is because competition between strains may select for genotypes that exploit host resources sooner, regardless of whether they would produce fewer new infections in the single genotype situation ([@b15]), and may be directly observed as an increase in the virulence of mixed infections, or changes in optimal virulence levels over evolutionary time. Some authors have proposed that treatment may reduce the incidence of multiple infections, and thus select for lower virulence \[e.g. ([@b49])\]. However, an important point to consider is that observed virulence will be a product of both parasite and host factors ([@b108]). Host defence against genetically heterogeneous infections may require more host resources or such defence may be less effective ([@b80]; [@b83]). A rise in virulence not necessarily based on parasite adaptation, or conversely, parasite diversity itself may be an important component of the development of adaptive immunity and hence protection from severe disease.

A feature of schistosome epidemiology is that infection intensity and disease severity vary considerably between geographic areas and between individuals within the same region whether due to age and duration of exposure, host or parasite genetic background and/or host behaviour. Laboratory studies, albeit currently limited to *S. mansoni,* have demonstrated that such variation can be attributed in some instances to repeatable differences in parasite strain ([@b88]; [@b63]; [@b21]; [@b113]) and there is preliminary evidence (from RAPD data) of an association of specific parasite genotypes with more intense pathology in *S. haematobium* ([@b17]). In the laboratory, schistosome traits including infectivity, rates of replication, transmission and virulence in both the definitive and intermediate hosts have been demonstrated not only to have a genetic basis, but to be sometimes genetically correlated with rapid responses to artificial selection clearly documented ([@b31]; [@b56]; [@b125], [@b127]). Different, and sometimes opposing, selective pressures acting on parasites within the intermediate and definitive hosts have been identified. These have been postulated to be crucial to the evolution of pathogens with multi-host lifecycles ([@b50]) and might be expected to promote polymorphisms in traits via fluctuating selection, whereby different genotypes, or selection for different alleles, will be favoured in the different obligatory host stages. Likewise, infection of hosts by multiple strains of parasite genotypes has been shown to be associated with exacerbated host morbidity as a result of intra-host parasite competition ([@b32]). However, intra-host competition has also been documented to favour strains of varying virulence phenotype in this system ([@b57]). Thus evolutionary alterations in schistosome life history characteristics in response to selection imposed by mass chemotherapy programs may well be likely, although the direction and strength of selection in endemic field situations is unknown. For example, if treatment were to favour schistosome evolutionary strategies that maximize transmission, an increase in egg production and concomitantly an increase in the morbidity of residual or untreated infections might be predicted. Conversely, treatment may reduce the incidence of multiple infections, and hence select for reduced parasite virulence.

In the field, and in the absence of genetic markers for parasite traits such as virulence and fecundity, the impact of mass chemotherapy on general parasite life-history traits could potentially be monitored through the integration of clinical measures and prevalence data with population genetic analyses using microsatellite markers. Such data may be valuable in monitoring relationships between prevalence, intensity and morbidity measures and associations of particular genotypes or degrees of genetic diversity in clinical phenotypes (such as population subdivision between areas or individuals with differing morbidity or infection intensity, which would suggest that parasite strain variability may be a potential contributing factor) and the effect of chemotherapeutic treatment on such associations. However, detecting alterations of parasite reproductive strategies is particularly difficult in schistosomes, as adult worm burdens cannot be assessed in living hosts, although population genetic studies may give some indications of changes having occurred. For example, a reduction in the genetic diversity of infections of similar intensity might be evidence of decreases in *per capita* egg production.

All organisms, including parasites, have limited resources that can be allocated to various functions such as growth, survival and reproduction. Maximizing fitness (lifetime reproductive success) may involve trade-offs between such traits. Strategies of resource allocation that maximize fitness can differ between benign and stressful environments, including that of stresses imposed by chemotherapy ([@b18]). Consequently natural selection often favours phenotypic alteration of reproductive effort in response to stress. For example, increased reproductive effort, termed fecundity compensation, should follow cues associated with a decreased probability of future survival or reproduction -- this has been observed in the enhanced egg production occurring in infected crickets ([@b1]), infected *Daphnia* ([@b20]) and snails that have been exposed to castrating parasites ([@b79]; [@b10]). Secondly, if conditions change such that one life history stage becomes relatively more vulnerable than another, increased investment into the least vulnerable stage is predicted \[the 'safe harbour' hypothesis ([@b102])\] Similar parasite life history counter-adaptations may be associated with the stresses imposed by human intervention strategies such as chemotherapy. For example, a subcurative dose of the antimalarial chloroquine has been demonstrated to cause malaria parasites to divert resources from within host asexual replication to the production of transmission stages (gametocytes) in a *Plasmodium chabaudi* laboratory model ([@b18]). These alterations lead to correlated changes in infectivity to mosquitoes, with the consequence that chloroquine treatment had no effect on the proportion of mosquitoes infected. Whilst such phenotypic plasticity may be less common in more complex multicellular organisms such as the helminth parasites, recent experimental studies of the fish trematode, *Coitocaecum parvum,* have suggested that they too can use information about transmission opportunities to trigger life history alterations. In this example accelerated development and precocious maturity of larvae in intermediate hosts was observed in the absence of either chemical cues emanating from the fish definitive host or the presence of high intermediate host mortality ([@b96]). Recent laboratory studies of *S. mansoni* have also shown that when intermediate hosts are stressed due, for example, to starvation, the resulting reduced parasite success in that intermediate host stage appears to be subsequently traded-off with increased parasite investment and subsequent success within the definitive host stage (C. M. Gower, L. Blair and J. P. Webster, unpublished data). Such studies further indicate that there may be phenotypic plasticity in this system that may aid maintenance of transmission in response to stress. If such mechanisms do exist, it might be predicted that human treatment would promote an increase in the reproductive importance of the snail component of the life history, and therefore, that the force of transmission may not be reduced as much as expected by reference to reductions in the intensity and prevalence of human infections. This further underlines the importance of morbidity reduction as the major goal of current schistosomiasis control programmes.

Impact of mass chemotherapy on interactions between different species of schistosome and between schistosomes and other parasites
=================================================================================================================================

In the developing world co-infections and polyparasitism within humans appear to be the rule rather than the exception. For example, co-infections between *S. mansoni* and *S. haematobium* have been reported in an increasing number of foci in sub-Saharan Africa ([@b27], [@b28]; [@b52]) and also with species of STHs ([@b16]; [@b109]; [@b45]). Inter-specific interactions between parasites are expected to occur when there are co-infections. One of the main characteristics of these interactions relates to whether they result in a positive or negative association between the abundances of different parasite species within the host. Facilitation refers to positive interactions, where infection of a host by one parasite species enables infection of that host by a second parasite species which would otherwise not be able to infect. Negative interactions occur due to inter-specific competition: the competition between two species of parasites co-infecting a host for limited niches and/or resources. Both types of interaction may be mediated by the host immune system through either suppression of the immune response allowing facilitation or stimulation of a immune response in the case of competition ([@b101]). Such synergistic or antagonistic interactions of co-infections may clinically affect individuals and co-endemicity may affect the epidemiology of the parasites ([@b65]). Polyparasitism may also be likely to have a large impact on both the parasites and the host involved as it may affect parasite growth, maturation, reproductive success and survival along with the susceptibility, morbidity and immune response of the host ([@b65]).

The effects of interactions between *S. haematobium* and *S. mansoni* on parasite dynamics were originally investigated in the field, where studies in Cameroon and Senegal revealed that in areas of overlap *S. mansoni* eggs were being excreted in urine samples of humans as opposed to the usual faecal route ([@b98]). This indicated that male *S. haematobium* worms and female *S. mansoni* worms (which cannot successfully hybridize) were pairing heterospecifically and migrating to the urinary oviposition site, resulting in *S. mansoni*-shaped eggs in the urine (through parthenogenesis). Laboratory studies revealed that *S. haematobium* males compete with, and are more successful than, *S. mansoni* males in pairing with *S. mansoni* females ([@b122]). When such competition exists in a system there is the risk of exclusion, either partially or totally, of one species by another and such mating competition has been implicated in limiting the distribution of another less common schistosome species, *S. intercalatum*, due to competitive interactions with *S. mansoni* ([@b110]). However, the outcome of such competition is difficult to predict as it relies on several factors relating to the individual parasite-life histories. These include the relative infectivity of the parasites, length of life-cycle (shorter for *S. mansoni*), sex ratio (more female biased for *S. mansoni*) and male competitive pairing ability (greater for *S. haematobium*). Indeed dominance in mating competition may in some cases result in a reduction in fecundity for the dominant species due to the fact that hybridization does not occur ([@b122]). In areas of overlap between *S. mansoni* and *S. haematobium* in Egypt, for example, *S. mansoni* has been observed to be replacing *S. haematobium* and at least in this focus *S. mansoni* appears to be competitively dominant ([@b2]). However, interactions between schistosomes and co-infecting STHs have not been so extensively studied. In many reports of the levels of co-occurrence for these two groups of parasites in the same individuals it appears that the parasites may be positively associated with each other and therefore undergoing positive inter-specific interactions such as facilitation of infection of one species by the other or synergistic effects on the host immune response once co-infected ([@b109]; [@b45]). Competitive interactions have, however, been identified despite this, through for example the observation of reduced infection intensities for *Ascaris lumbricoides* and *S. mansoni* in co-infections in comparison to individual infections ([@b45]). In all such work based on field observations, care must be taken, nevertheless, in the interpretations of simple correlations between the abundances of different parasite species within hosts. Many factors other than competition or facilitation could influence such patterns, including the nutritional state or immunocompetence of the host, host behaviour and the environment of the host population.

Mass chemotherapy may be predicted to impact on such complex dynamic interspecific interactions, especially if the selection pressure differs between the parasite species. For example effects will be observed if PZQ efficacy is different for *S. mansoni* and *S. haematobium* or if the efficacy of PZQ on schistosome infections is different to that of albendazole for STHs. Indeed, as regards the former, whilst PZQ works on all species of schistosome infecting humans*,*, there is some evidence of differential susceptibility, where potential tolerance (or even resistance) to *S. mansoni* has been detected but not for *S. haematobium* ([@b107]). Moreover, as *S. mansoni* and *S. haematobium* differ in the generation times/length of time to maturation, and as juveniles schistosomes are not susceptible to PZQ, this too could potentially lead to differences between these two species. Such differences could affect the order of establishment of the parasites within their human hosts \[a factor known to be very important in determining the outcome of inter-specific competition ([@b26])\]. Also, if for example, PZQ resistance was to develop in one schistosome species (say *S. mansoni*) it could not be passed between the species (due to their inability to hybridize). One could hypothesize that in conditions of high drug imposed selection this could lead to *S. mansoni* having increased competitive dominance over *S. haematobium* in areas of overlap. However in conditions of reduced drug imposed selection (possibly due to the identification of such drug resistance in the *S. mansoni* species), *S. haematobium* could be competitively dominant due to inherent costs in *S. mansoni's* drug resistance. A comparable scenario could also be imagined with relation to drug resistance emerging for either schistosomes or STHs. Such theories, although somewhat speculative at this stage, highlight the importance of monitoring and evaluating the impact of mass chemotherapy control programmes on such inter-specific interactions. Limited evidence is just emerging of possible competitive interactions. For example, one study found an increase of intestinal schistosomiasis after PZQ treatment in a *S. haematobium* and *S. mansoni* mixed focus in Senegal ([@b37]). In one village, where the two parasites were present before treatment, the disappearance of the urinary schistosomiasis after treatment was concomitant with a dramatic increase of intestinal schistosomiasis: *S. mansoni* egg excretion was seven times higher than before treatment. The direct cause of this change is unknown. However possible reasons include lack of activity of PZQ against *S. mansoni* in this focus, a reduction in mating competition, within which *S. haematobium* is dominant ([@b122]), and/or the fact that it was a developing (epidemic) focus.

Inter-specific interactions may also be predicted to directly impact morbidity, as well as affecting the prevalence and intensity of human infections. For example, positive associations between mixed infections of different species of schistosomes and of schistosomes and STHs, and increases in parasite infection intensity have been observed ([@b16]; [@b109]; [@b45]). However, associated increases in morbidity have not yet been determined. One study on interactions between *S. mansoni* and *S. haematobium* has identified a potential effect of inter-specific interactions on host morbidity. This study did not support the speculative evolutionary theory which predicts that more diverse infections are more costly to the host ([@b6]; [@b13]; [@b89]; [@b8]; [@b77]; [@b47]). Instead it reported a lowering of *S. mansoni* induced morbidity (hepatomegaly and splenomagaly morbidity) in mixed infections with *S. haematobium* relative to that observed for *S. mansoni* single infections ([@b29]). The authors suggest that this lowering effect on liver morbidity could be due to *S. haematobium* males mating with *S. mansoni* females with the eggs from such couplings passing to the urinary tract (the *S. mansoni* females will lay parthenogenic eggs shaped like normal *S. mansoni* eggs and the *S. haematobium* male will carry the female to the normal *S. haematobium* egg-laying site, i.e. the urinary tract, resulting in *S. mansoni*-shaped eggs in urine), thereby reducing the amount of classical *S. mansoni* induced morbidity. The consequence of typical *S. haematobium*-associated bladder pathology was not, however, investigated in this preliminary study on mixed species infections, and further work to evaluate this is underway ([@b55]). The effects of chemotherapeutic treatment on such inter-specific interactions between parasites generally may well be predicted to have implications for the morbidity induced by such mixed infections on human hosts, due to a general lowering effect of treatment on infection prevalences of each, or one or other, of the separate parasites species.

Co-evolutionary interactions between schistosomes and their molluscan intermediate host
=======================================================================================

Mass chemotherapy programs might also be likely to affect co-evolutionary interactions between helminths and their hosts, particularly in those with part of the lifecycle in short-lived intermediate hosts, whose generation times are roughly similar to those of their infecting parasites, such as schistosomes and their freshwater snail hosts. Snail-trematode compatibility is a highly specific relationship, often at the population or strain levels for both participants ([@b74]; [@b120]; [@b118]; [@b119]). This specificity has the important practical effect of limiting medically important trematodes such as schistosomes to geographic areas occupied by compatible snails ([@b67]). Studies have demonstrated both that snail resistance to schistosome infection is a heritable genetic trait ([@b74]; [@b120]; [@b118]; [@b119]) and that schistosome infection presents a significant fitness cost to host snails in terms of increased mortality and reduced fertility ([@b128]; [@b121]). However, natural host populations often exhibit considerable genetic variability in resistance to parasitism. Co-evolutionary theory suggests that one potential mechanism for maintaining such diversity is a trade-off between fitness costs associated with resistance and fitness costs associated with parasitism ([@b75]; [@b48]; [@b46]). Examples of such as a cost of resistance in snails to their schistosomes, in terms of reduced egg fertility but not necessarily fecundity, have been demonstrated ([@b121]). Selection for susceptible snails, mediated by the high costs of resistance, also has wider implications for schistosomiasis control measures. Most importantly, if a reduction in net transmission rates due to mass chemotherapy favours an increase in the susceptibility of the snail population, then this may increase the likelihood of the re-emergence of the disease should control measures be relaxed. This could serve to reinforce any increased susceptibility of the human population due to loss of, or a reduction in, acquired immunity.

Impact of mass chemotherapy on human hosts
==========================================

The potential impacts of mass chemotherapy programmes on parasites and intermediate hosts are also important in relation to their overall effect on infection intensity and virulence of schistosomes within their human host. Mass chemotherapy control programmes may, however, also be predicted to impact on human hosts directly. It is now widely accepted that humans exhibit an acquired immunity to schistosome infections which develops slowly as individuals' age and accumulate exposure experiences. In schistosome endemic areas, human infection levels typically increase during childhood, peak during adolescence and decline during adulthood ([@b60]; [@b86]), a pattern which is in part attributed to cumulative exposure to infection and the development of gradually acquired resistance to schistosomes, and in part due to behavioural changes with age that are related to exposure to infection. Some parasite antigens that are thought to play some part in stimulating such protective acquired immunity are located beneath the worm tegument of adult schistosomes and are therefore only available to the immune systems when the tegument is damaged or worms die ([@b85]). Adult schistosome worms are known to live for, on average, between 3 and 7 years. If these antigens beneath the worm tegument are the key stimulants of acquired immunity, this observation on life expectancy may be linked with the fact that it takes several years for infected children to 'acquire' resistance ([@b85]). The potential effects of mass chemotherapy on host acquired resistance have been extensively studied. Mass chemotherapy control programmes may be predicted to prevent the development of naturally acquired resistance to infection, and may therefore have detrimental effects, at least in terms of the proportion of humans infected, if control ceases and individuals continued to be highly infected at older ages without having developed any acquired immunity during childhood. Similar concerns apply for the control of many parasitic infections such as the malarial parasites. However, studies to date indicate that the exposure of the host immune system to parasite antigens through the damage and subsequent killing of adult schistosome worms by the action of PZQ actually stimulates a form of acquired immunity itself. This 'chemotherapy-induced' acquired immunity has been shown to be different to naturally acquired immunity ([@b25]; [@b9]), possibly due to differences between the large amounts of antigens from adult worms released over a small time period directly into the host bloodstream due to PZQ action. In contrast, in the absence of treatment smaller amounts of various antigens are released over a long period of time through the skin, lungs, liver and the blood from adult and juvenile worms ([@b85]). There is ongoing debate as to the effectiveness of such treatment-acquired-immunity in comparison to naturally acquired immunity in relation to the amount and duration of protection that it provides ([@b9]). Nevertheless, it may well be of value to monitor the effectiveness of such treatment-acquired immunity in relation to mass chemotherapy control programmes over space and time. One way to do this may be to measure reinfection rates by age group, discounting for the herd impact of mass treatment, to see if this drug induced immunity reduces establishment of the adult worms.

Mass chemotherapy schistosomiasis control programmes do not only involve the administration of chemotherapy, but also the provision of health education. Health education may be predicted to have a large effect on humans if it achieves its aim of changing human water-contact behaviour. Two facets of human water-contact behaviour are important; human defecation and urination into water containing schistosome intermediate host snails and human contact with water containing infective schistosome cercariae. Changes in these two facets of water contact are likely to have different relative effects in terms of human exposure to schistosomes, as well as broader aspects of the transmission dynamics of schistosome populations. A complete cessation in contact with water containing cercariae would prevent human schistosome infection. However, considering the current infrastructure in communities with endemic schistosomiasis this is not a likely outcome of such control programmes. Instead some degree of reduction in both of these types of water contact is possible and they would be expected to reduce prevalence and infection intensity for human hosts in general, and thereby also potentially impact the selective pressures imposed upon parasite virulence and/or other life history traits.

Impact of mass chemotherapy relating to nonhuman definitive hosts
=================================================================

Although mass chemotherapy programmes are specifically directed at reducing human morbidity, they may have implications for other definitive hosts of schistosomes. For example, mass chemotherapy may be important both in terms of their effects on these hosts (which may potentially be important livestock) but also for their role previously discussed as *refugia* and also as reservoirs for re-infection of human hosts. The number of nonhuman definitive hosts vary greatly between the schistosome species with *S. haematobium* being almost exclusively a human parasite, *S. mansoni* infecting humans, rodents and primates ([@b81]; [@b84]) and *S. japonicum* infecting humans and a very wide range of nonhuman hosts ([@b117]). The importance of nonhuman hosts as both sources of reinfection, and conversely as *refugia*, will depend on whether the parasite population is panmitic or whether parasite strains are present which are circulating independently within hosts of different types. For example, cross-infections have been demonstrated to be rare between *Ascaris* nematodes of humans and pigs in sympatric areas ([@b5]). Thus, although infections of humans are unlikely to occur from pig-derived parasite populations, these populations won't act as natural *refugia* either unless at some point they come into contact with human--derived worms. Wang and colleagues also used microsatellite markers to examine *S. japonicum* across a range of host species in China and reported that parasites were circulating between humans and all the domestic animals species studied, although with some strain structure present and greatest potential transfer between humans and bovines, at least within the marshland regions ([@b117]).

Mass chemotherapy treatment may be predicted to impact on the infection of nonhuman definitive hosts as any 'human adapted strains' would be killed via PZQ treatment in humans giving any 'nonhuman host' adapted strains a distinct competitive advantage. It is likely therefore, that there will be strong selective pressure for further adaptation of schistosomes to their nonhuman hosts which may have detrimental effects for these hosts. Conversely for human hosts different scenarios may be predicted relating to the extent to which schistosomes adapt to transmission in these nonhuman hosts. If PZQ treatment in human hosts imposes a very strong selection pressure on parasites to adapt to their nonhuman hosts, then schistosomes may adapt to solely infect these nonhuman hosts. Indeed there appears to be clear evidence of this already happening in response to differing environmental selective pressures being imposed on schistosomes in Guadeloupe, with the recent adaptation of *S. mansoni* (back) to its rodent host ([@b111]; [@b112]) and an associated potential decrease in risk of further human infection. With intermediate levels of selection pressure imposed by PZQ treatment it may conversely be predicted that schistosome infections within nonhuman hosts may act as reservoirs for human re-infection. Indeed there are data to suggest this may already be occurring within both *S. mansoni* ([@b84]) and *S. japonicum* (D. Lu, J. Rudge, T. Wang and J. P.Webster, unpublished data).

Conclusions and recommendations
===============================

Recently implemented mass-chemotherapeutic control programmes have been shown to have a rapid and dramatic impact on reducing schistosome prevalence, intensity and subsequent human host morbidity. However, as control efforts gather pace across sub-Saharan Africa the wider availability of PZQ may exacerbate the risk of the emergence of drug-resistant parasites. This provides a strong incentive to extend monitoring and surveillance and to increase investigation of the population biology and genetics of potentially resistant parasites and the fine detail of resistance mechanisms. Unfortunately to date there are very limited empirical data available relating to any natural genetic diversity in schistosome, or indeed any helminth, populations or how any of the variations observed in the few published studies influence the biology of the parasite and its clinical impact on humans or animals. This situation for helminths is in marked contrast to that pertaining for most other important pathogens of humans -- especially the viruses and bacteria -- where large international databases exist recording sequence variation in isolates from different clinical and epidemiological settings. Given the growth in interest in the community based control of helminth infections by chemotherapy, much greater attention needs to be directed towards recording genetic diversity in a systematic manner in databases that also reflect epidemiological and treatment experience. Records of sequence variation need to take account of the fact that over the last 40 years schistosome research has been over-dependent on laboratory-reared parasites repeatedly passaged through a variety of mouse strains, which we know may not represent the field population ([@b104]; [@b58]).

Evolutionary theory has a role in the design, application and interpretation of such programmes. It is perhaps most important here in terms of identifying where change may occur in the host parasite system as a result of PZQ treatment and therefore allowing us to design effective monitoring processes to identify if and in which direction these changes actually occur ([Table 1](#tbl1){ref-type="table"}). Whilst there may well be currently limited evidence (and/or studies performed to look for it) that evolutionary changes in natural schistosome or host populations have occurred as a result of current PZQ control efforts, it is axiomatic that such changes are expected under the intensity of selection created by community based control interventions. However, their relative importance to the success of control programmes will be determined by the speed of parasite adaptive evolution, and the genetic variation present upon which selection may act, which may itself be reduced by mass chemotherapy treatment. In foci where local eradication is possible, schistosomes may not evolve sufficiently rapidly to undergo substantial life history adaptation before elimination. However, it must be considered, that the major focus of current schistosomiasis control programs is morbidity, rather than transmission control, and thus evolutionary considerations are greater in this context than perhaps in control programs attempting parasite eradication. The imperative to control these debilitating infections using the best tool available (i.e. chemotherapy) is obvious. However, we do suggest that consideration of control measures from an evolutionary standpoint is of importance given the history of the impact of wide scale chemotherapeutics on the evolution of resistance across a very wide range of organisms. Continued monitoring and evaluation of parasites and their hosts whenever and wherever transmission remains must become an essential arm of intervention. For schistosomes, concerns over the evolution and rapid spread of resistance are somewhat less than for most pathogens for reasons explained in this review but especially the large predicted *refugia* and fitness costs involved. Nevertheless, it must not be forgotten that schistosomes have already evolved resistance to oxamniquine ([@b64]; [@b23]; [@b40]; [@b41]; [@b12]). Schistosome control programmes such as that of the SCI in sub-Saharan Africa have, wherever logistically and financially feasible, already integrated such detailed evolutionary/resistance monitoring and evaluation of host and parasite factors. In addition to the parasite prevalence, intensity and subsequent parasite-induced morbidity levels closely monitored in each population, SCI monitors the genotype and phenotype of the parasite at baseline, prior to the new chemotherapeutic intervention, and then, both in the population overall, but specifically in identifiable age-structure longitudinal cohorts of children over space, time and treatment history, to observe the effect on epidemiological patterns and parasite genetic diversity.

###### 

Specific example predictions for the potential effect of mass chemotherapy schistosomiasis control programmes on parasites and their hosts and the ways in which each of these may be monitored.

  Prediction                                                                                              
  ------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------
  Drug resistance may develop                                                                             Monitoring of drug efficacy and population genetic surveys. Development of molecular markers
  Treatment may alter optimal parasite virulence; treatment may reduce incidence of multiple infections   Patterns of relationship of intensity, genetic diversity and morbidity before and after treatment
  Treatment may alter competitive balance or interactions with other infections                           Alterations in epidemiological patterns pre- and post-treatment in terms of intensity and prevalence of coinfections
  Treatment may promote investment in other stages of the schistosome lifecycle                           Monitoring of snail infection rates and prevalences; might predict no difference in force of infection even with decreasing human infection

It is unethical to withhold treatment for individuals in order to obtain 'control' data of parasites over space and time within such mass control programmes. However, by examining the parasites, either repeatedly within countries prior to mass drug implementation, and the cercariae released from the sympatric snail intermediate host populations, and in conjunction with the miracidia released from the new 6--7-year-old child recruits at each site and over each year, it is possible to elucidate the potential impact on the parasite populations. Much still remains to be achieved, and indeed the requirement of novel molecular markers for PZQ-resistance are central to an improved understanding. We recommend that where at all possible all future large scale human and indeed animal helminthiasis-control programmes initiate detailed monitoring and evaluation of host and parasite genetic diversity factors from their onset. In making this recommendation we fully recognize the cost implications but the trend in sequencing costs at least give optimism that this type of monitoring can be without detriment to the resources directed at morbidity control.
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